Browsing by Autor "Po-Ya Chuang"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
Item type: Item , Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia(Taylor & Francis, 2026) Sikander Ailawadhi; Swetha Challagulla; Po-Ya Chuang; Wesley Furnback; Keri YangThis real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU than acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.